Page 11 - Ipca Labs News Today

According to total sales audit data from worlds largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent yoy in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base effect in April, 2020 and sharp surge in Covid-19-related sales.

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector. According to total sales audit data from worlds largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent yoy in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base effect in April, 2020 and sharp surge in Covid-19-related sales. On the MAT (moving annual turnover) basis, IPM grew 9.6 per cent,...

Amid COVID Surge, Indian Pharma Sector Witnesses Exponential Growth In April 2021: Report A Representative Image The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector. According to total sales audit data from world’s largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent year on year (yoy) in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base...

Investors poorer by Rs 8.69 lakh crore as Covid 2.0 spooks D-Street bulls SECTIONS Share Synopsis Further imposition of lockdowns and all-time high Covid-19 cases have dragged the market to a monthly low. The S&P BSE Sensex index tumbled 1,897.88 points or 3.82% to hit 47,693.44 at the weakest level during the session. Related NSE Explore Now NEW DELHI: As India recorded its highest ever surge in new Covid-19 cases, investors dumped whatever they could get their hands on, pushing benchmark in...

Pharma Shares Gain On Higher Demand For Medicines As Covid-19 Cases Rise Pharma Shares Gain On Higher Demand For Medicines As Covid-19 Cases Rise Rising Covid-19 cases in the country is leading to higher demand for medicines which is driving up the share prices of drugmakers, analysts said. Updated: April 12, 2021 12:30 pm IST Shares of pharma companies were outperforming in an otherwise weak market session as rising demand for medicines amid rising Coronavirus infections in country led to ...

With its 100 billionaires, Beijing has more than any other city in the world  It over-took New York City - with 99 - in this years Forbes Worlds Billionaire List  Chinas capital added 33 new billionaires in the last year, despite the pandemic China was the only major world economy to grow at all last year amid Covid-19 The richest person in Beijing was Zhang Yiming, the founder of the app TikTok

ChrysCapital announces investment in Corona Remedies ​ By IANS | Published on ​ Mon, Apr 5 2021 20:57 IST | ​ 9 Views   CFMA sees poetic justice for MF investors through 6 FTMF shut funds case in SC.. Image Source: IANS News New Delhi, April 5 : ChrysCapital, one of the leading private equity funds in India, has announced its investment in Corona Remedies Private Limited (Corona), one of the countrys fastest growing pharmaceutical companies, by acquiring a 27 per cent stake through ...

Ipca Labs on strong growth path: Why this pharma company is stock pick of the week The stock pick of the week, IPCA Labs Synopsis Ipca with its vertical integration, cost advantage and strong export business has been able to manage good set of numbers. Having a strong balance sheet with low debt/equity ratio despite being in an investment phase is another positive for this counter which has made it a favourite of analysts. Ipca Labs, a mid-sized pharma company continues to report good numbers a...

Here are a few stocks which may buzz the most in todays trade.

Explore Now NEW DELHI: Drug firm Ipca Laboratories on Thursday reported a 35.44 per cent rise in consolidated net profit to Rs 267.56 crore for the third quarter ended December 2020, on the back of robust sales in domestic and international markets. The company had posted a net profit of Rs 197.54 crore for the same period of the previous fiscal, Ipca Labs said in a BSE filing. Its consolidated total income stood at Rs 1,425.21 crore for the quarter under consideration. It was Rs 1,230.99 cror...